PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia

To assess the effectiveness and safety of PCSK9 inhibitors in the primary prevention of IHD in people with HeFH.

This is a protocol.

Health topics:

Child health > Genetic disorders > Inborn errors of metabolism

Published:

9 January 2018

Authors:

Ryan A, Nevitt SJ, Byrne CD, Cook P

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Ryan A, Nevitt SJ, Byrne CD, Cook P. PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD012917. DOI: 10.1002/14651858.CD012917